Amarin Corp PLC (AMRN) stock
AMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 10/3061% above fair value
$11.26−0.01 (-0.09%)
Close on Nov 18, 2026Market cap $248.90MP/E –Yield –
Amarin r&d expenses
Research and development expenses are spending on new products and technology.
Amarin's R&D Expenses for the twelve months ending Sep 30, 2026 was $19.01M, down 6.9% year over year. For fiscal 2025 it was $19.81M, down 5.1% from the year before. Over ten years it grew -9.0% a year on average. The highest annual figure on record is $72.75M in fiscal 2013.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.81M | -5.1% |
| FY2024 | Dec 31, 2024 | $20.87M | -6.1% |
| FY2023 | Dec 31, 2023 | $22.22M | -26.9% |
| FY2022 | Dec 31, 2022 | $30.41M | +3.8% |
| FY2021 | Dec 31, 2021 | $29.31M | -24.8% |
| FY2020 | Dec 31, 2020 | $38.96M | +13.3% |
| FY2019 | Dec 31, 2019 | $34.39M | -38.5% |
| FY2018 | Dec 31, 2018 | $55.90M | +18.5% |
| FY2017 | Dec 31, 2017 | $47.16M | -5.6% |
| FY2016 | Dec 31, 2016 | $49.98M | -2.1% |
| FY2015 | Dec 31, 2015 | $51.06M | +1.5% |
| FY2014 | Dec 31, 2014 | $50.33M | -30.8% |
| FY2013 | Dec 31, 2013 | $72.75M | +23.4% |
| FY2012 | Dec 31, 2012 | $58.96M | +172.9% |
| FY2011 | Dec 31, 2011 | $21.60M | -22.9% |
| FY2010 | Dec 31, 2010 | $28.01M | +34.1% |
| FY2009 | Dec 31, 2009 | $20.89M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.21M | -0.1% |
| Q2 FY2026 | Jun 30, 2026 | $4.77M | -2.9% |
| Q1 FY2026 | Mar 31, 2026 | $4.67M | -12.2% |
| Q4 FY2025 | Dec 31, 2025 | $5.37M | -10.3% |
| Q3 FY2025 | Sep 30, 2025 | $4.21M | -7.3% |
| Q2 FY2025 | Jun 30, 2025 | $4.92M | +3.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.31M | -5.1% |
| Q4 FY2024 | Dec 31, 2024 | $5.99M | +3.4% |
| Q3 FY2024 | Sep 30, 2024 | $4.54M | -11.1% |
| Q2 FY2024 | Jun 30, 2024 | $4.75M | -15.9% |
| Q1 FY2024 | Mar 31, 2024 | $5.60M | -1.5% |
| Q4 FY2023 | Dec 31, 2023 | $5.79M | +10.5% |
| Q3 FY2023 | Sep 30, 2023 | $5.11M | -11.4% |
| Q2 FY2023 | Jun 30, 2023 | $5.64M | -39.7% |
| Q1 FY2023 | Mar 31, 2023 | $5.68M | -43.5% |
| Q4 FY2022 | Dec 31, 2022 | $5.24M | -8.9% |
| Q3 FY2022 | Sep 30, 2022 | $5.77M | -26.3% |
| Q2 FY2022 | Jun 30, 2022 | $9.36M | +47.2% |
| Q1 FY2022 | Mar 31, 2022 | $10.05M | +7.2% |
| Q4 FY2021 | Dec 31, 2021 | $5.75M | -32.4% |
| Q3 FY2021 | Sep 30, 2021 | $7.82M | -23.4% |
| Q2 FY2021 | Jun 30, 2021 | $6.36M | -36.2% |
| Q1 FY2021 | Mar 31, 2021 | $9.38M | -8.8% |
| Q4 FY2020 | Dec 31, 2020 | $8.51M | -23.3% |
| Q3 FY2020 | Sep 30, 2020 | $10.20M | +14.4% |
| Q2 FY2020 | Jun 30, 2020 | $9.97M | +39.8% |
| Q1 FY2020 | Mar 31, 2020 | $10.28M | +41.9% |
| Q4 FY2019 | Dec 31, 2019 | $11.10M | -6.8% |
| Q3 FY2019 | Sep 30, 2019 | $8.92M | -36.6% |
| Q2 FY2019 | Jun 30, 2019 | $7.13M | -60.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.24M | -38.4% |
| Q4 FY2018 | Dec 31, 2018 | $11.91M | -0.3% |
| Q3 FY2018 | Sep 30, 2018 | $14.07M | +31.6% |
| Q2 FY2018 | Jun 30, 2018 | $18.16M | +32.6% |
| Q1 FY2018 | Mar 31, 2018 | $11.76M | +8.7% |
| Q4 FY2017 | Dec 31, 2017 | $11.95M | +17.4% |
| Q3 FY2017 | Sep 30, 2017 | $10.69M | – |
| Q2 FY2017 | Jun 30, 2017 | $13.69M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.82M | – |
| Q4 FY2016 | Dec 31, 2016 | $10.18M | – |
See a number that looks wrong?